Treatment of recurrent severe hemoptysis in cystic fibrosis with tranexamic acid.
Major hemoptysis is a potentially life-threatening complication of cystic fibrosis (CF) lung disease. Bronchial artery embolization (BAE) along with treatment of a CF pulmonary exacerbation has become the most widely used therapeutic approach for major hemoptysis in CF. However, BAE has been associated with severe complications, especially when bronchial artery to spinal artery anastomoses are present. This case study describes the successful treatment of major hemoptysis in CF with tranexamic acid, in an individual in whom 12 previous BAE procedures had been performed and further procedures were contraindicated secondary to bronchial artery to spinal artery collaterals. Recurrence of the hemoptysis occurred after attempts had been made to withdraw the tranexamic acid. Tranexamic acid was resumed with resolution of the hemoptysis, and the therapy has been used continuously for 13 months without any complications.
Graff
G R
GR
Department of Child Health, University of Missouri-Columbia, 65212, USA. graffg@health.missouri.edu
D000328:Adult; D003550:Cystic Fibrosis / Q000150:complications* / Q000175:diagnosis; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006469:Hemoptysis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D012008:Recurrence; D012720:Severity of Illness Index; D014148:Tranexamic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome
D014148:Tranexamic Acid